BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 10803497)

  • 1. Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1).
    Yu T; Bai Y; Dierich MP; Chen YH
    Microbiol Immunol; 2000; 44(2):105-10. PubMed ID: 10803497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1.
    Lu Y; Xiao Y; Ding J; Dierich M; Chen YH
    Int Arch Allergy Immunol; 2000 Jan; 121(1):80-4. PubMed ID: 10686512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
    Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
    Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
    Tian H; Xiao Y; Qin L; Chen YH
    Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1.
    Ding J; Lu Y; Chen Y
    FEMS Immunol Med Microbiol; 2000 Oct; 29(2):123-7. PubMed ID: 11024351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and specificity of the candidate multi-epitope-vaccines against HIV-1.
    Lu Y; Ding J; Chen YH
    Immunopharmacol Immunotoxicol; 2001 Nov; 23(4):487-94. PubMed ID: 11792008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV epitope-peptides in aluminum adjuvant induced high levels of epitope-specific antibodies.
    Tian H; Xiao Y; Zhu M; Chen YH
    Int Immunopharmacol; 2001 Apr; 1(4):763-8. PubMed ID: 11357888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
    Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
    Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
    Boudet F; Keller H; Kieny MP; Thèze J
    Mol Immunol; 1995 May; 32(7):449-57. PubMed ID: 7783749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
    Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
    J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits.
    Rangasamy SP; Menon V; Dhopeshwarkar P; Pal R; Vaniambadi KS; Mahalingam S
    Vaccine; 2016 May; 34(21):2444-2452. PubMed ID: 27032514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.
    Robert-Guroff M; Louie A; Myagkikh M; Michaels F; Kieny MP; White-Scharf ME; Potts B; Grogg D; Reitz MS
    J Virol; 1994 Jun; 68(6):3459-66. PubMed ID: 7514675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 V3 loop crown epitope-focused mimotope selection by patient serum from random phage display libraries: implications for the epitope structural features.
    Gazarian KG; Palacios-Rodríguez Y; Gazarian TG; Huerta L
    Mol Immunol; 2013 Jun; 54(2):148-56. PubMed ID: 23270686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.
    Rubinstein A; Goldstein H; Pettoello-Mantovani M; Mizrachi Y; Bloom BR; Furer E; Althaus B; Que JU; Hasler T; Cryz SJ
    AIDS; 1995 Mar; 9(3):243-51. PubMed ID: 7755912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody.
    Xiao Y; Zhao Y; Lu Y; Chen YH
    Immunol Invest; 2000 Feb; 29(1):41-50. PubMed ID: 10709845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.